Adaptive Biotechnologies ADPT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $295.41M+6.7% | $276.98M+9.6% | $252.75M+23.2% | $205.22M+8.3% | $189.53M+5.9% | ||
| $73.09M+2.4% | $71.36M+0.3% | $71.18M+2.1% | $69.69M-1.9% | $71.01M-1.5% | ||
| $222.32M+8.1% | $205.62M+13.2% | $181.57M+34.0% | $135.53M+14.3% | $118.52M+10.9% | ||
| 75.3%+1.0pp | 74.2%+2.4pp | 71.8%+5.8pp | 66%+3.5pp | 62.5%+2.8pp | ||
| $93.19M-0.6% | $93.77M-1.5% | $95.2M-0.5% | $95.69M-1.3% | $96.91M-5.9% | ||
| $97.87M+3.5% | $94.57M+3.2% | $91.67M+3.3% | $88.75M+3.8% | $85.49M+0.9% | ||
| $76.29M+4.9% | $72.7M+2.1% | $71.2M+1.0% | $70.5M-0.2% | $70.61M-3.0% | ||
| $342.13M+2.4% | $334.1M+1.0% | $330.94M+1.4% | $326.33M-2.0% | $332.92M-2.5% | ||
| -$46.73M+18.2% | -$57.12M+26.9% | -$78.19M+35.4% | -$121.11M+15.5% | -$143.39M+11.8% | ||
| -15.8%+4.8pp | -20.6%+10.3pp | -30.9%+28.1pp | -59%+16.6pp | -75.7%+15.2pp | ||
| -$49.68M+16.5% | -$59.5M+25.3% | -$79.61M+34.3% | -$121.23M+14.5% | -$141.84M+11.1% | ||
| -16.8%+4.7pp | -21.5%+10.0pp | -31.5%+27.6pp | -59.1%+15.8pp | -74.8%+14.3pp | ||
| -$0.33+17.5% | -$0.40+24.5% | -$0.53+34.6% | -$0.81+14.7% | -$0.95+12.0% | ||
| -$29.79M+24.2% | -$39.29M+34.6% | -$60.1M+41.6% | -$102.84M+17.5% | -$124.62M+13.0% | ||
| -10.1%+4.1pp | -14.2%+9.6pp | -23.8%+26.3pp | -50.1%+15.6pp | -65.8%+14.3pp | ||
| -$46.73M+18.2% | -$57.12M+26.9% | -$78.19M+35.4% | -$121.11M+15.5% | -$143.39M+11.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Adaptive Biotechnologies's revenue?
- Adaptive Biotechnologies (ADPT) generated $295.4M in revenue over the trailing twelve months, up 55.9% year over year.
- Is Adaptive Biotechnologies profitable?
- Adaptive Biotechnologies is not currently profitable: it reported a net loss of $49.7M over the trailing twelve months, a -16.8% net margin.
- What are Adaptive Biotechnologies's profit margins?
- Gross margin is 75.3% and operating margin is -15.8%, with a -16.8% net margin.
- What is Adaptive Biotechnologies's earnings per share?
- Adaptive Biotechnologies's diluted EPS over the trailing twelve months is $-0.33.
- Where does Adaptive Biotechnologies's income statement data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
